ERDEM, Hakan, Esra KOCOGLU, Handan ANKARALI, Rehab EL-SOKKARY, Atousa HAKAMIFARD, Ridvan KARAALI, Sholpan KULZHANOVA, Amani EL-KHOLY, Hamed Azhdari TEHRANI, Reham KHEDR, Ayse KAYA-KALEM, Nenad PANDAK, Meliha CAGLA-SONMEZER, Summiya NIZAMUDDIN, Hande BERK-CAM, Rahmet GUNER, Jehan Ali ELKHOLY, Ferran LLOPIS, Andrea MARINO, Roman STEBEL, Balint Gergely SZABO, Maya BELITOVA, Elias FADEL, Tarkan YETISYIGIT, Yasemin CAG, Sevil ALKAN, Bircan KAYAASLAN, Serkan ONCU, Mehmet OZDEMIR, Mesut YILMAZ, Arzu Cennet ISIK, Dilsah BASKOL, Gulden SINCAN, Antonio CASCIO, Safak OZER-BALIN, Nesibe KORKMAZ, Rezaul Karim RIPON, Salma ABBAS, Irina Magdalena DUMITRU, Gulden ESER-KARLIDAG, Massimiliano LANZAFAME, Abdur RAFEY, Aun RAZA, Oguz Resat SIPAHI, Ilad Alavi DARAZAM, Umran ELBAHR, Ilknur ERDEM, Pinar ERGEN, Cemil BILIR, Hulya CASKURLU, Aysegul ERDEM, Mateja Jankovic MAKEK, Mustafa ALTINDIS, Botond LAKATOS, Catalina Mihaela LUCA, Esmeray Mutlu YILMAZ, Emmanuel NSUTEBU, Rumeysa CAKMAK a Fatma SIRMATEL. Prospective analysis of febrile neutropenia patients with bacteraemia: the results of an international ID-IRI study. International Journal of Antimicrobial Agents. Amsterdam, Netherlands: Elsevier Ltd, 2023, roč. 62, č. 3, s. 1-10. ISSN 0924-8579. Dostupné z: https://dx.doi.org/10.1016/j.ijantimicag.2023.106919.
Další formáty:   BibTeX LaTeX RIS
Základní údaje
Originální název Prospective analysis of febrile neutropenia patients with bacteraemia: the results of an international ID-IRI study
Autoři ERDEM, Hakan (792 Turecko, garant), Esra KOCOGLU (792 Turecko), Handan ANKARALI (792 Turecko), Rehab EL-SOKKARY (818 Egypt), Atousa HAKAMIFARD (364 Írán), Ridvan KARAALI (792 Turecko), Sholpan KULZHANOVA (398 Kazachstán), Amani EL-KHOLY (818 Egypt), Hamed Azhdari TEHRANI (364 Írán), Reham KHEDR (818 Egypt), Ayse KAYA-KALEM (792 Turecko), Nenad PANDAK (512 Omán), Meliha CAGLA-SONMEZER (792 Turecko), Summiya NIZAMUDDIN (586 Pákistán), Hande BERK-CAM (792 Turecko), Rahmet GUNER (792 Turecko), Jehan Ali ELKHOLY (818 Egypt), Ferran LLOPIS (724 Španělsko), Andrea MARINO (380 Itálie), Roman STEBEL (203 Česká republika, domácí), Balint Gergely SZABO (348 Maďarsko), Maya BELITOVA (100 Bulharsko), Elias FADEL (48 Bahrajn), Tarkan YETISYIGIT (48 Bahrajn), Yasemin CAG (792 Turecko), Sevil ALKAN (792 Turecko), Bircan KAYAASLAN (792 Turecko), Serkan ONCU (792 Turecko), Mehmet OZDEMIR (792 Turecko), Mesut YILMAZ (792 Turecko), Arzu Cennet ISIK (792 Turecko), Dilsah BASKOL (792 Turecko), Gulden SINCAN (792 Turecko), Antonio CASCIO (380 Itálie), Safak OZER-BALIN (792 Turecko), Nesibe KORKMAZ (792 Turecko), Rezaul Karim RIPON (50 Bangladéš), Salma ABBAS (586 Pákistán), Irina Magdalena DUMITRU (642 Rumunsko), Gulden ESER-KARLIDAG (792 Turecko), Massimiliano LANZAFAME (380 Itálie), Abdur RAFEY (586 Pákistán), Aun RAZA (586 Pákistán), Oguz Resat SIPAHI (792 Turecko), Ilad Alavi DARAZAM (364 Írán), Umran ELBAHR (48 Bahrajn), Ilknur ERDEM (792 Turecko), Pinar ERGEN (792 Turecko), Cemil BILIR (792 Turecko), Hulya CASKURLU (792 Turecko), Aysegul ERDEM (792 Turecko), Mateja Jankovic MAKEK (191 Chorvatsko), Mustafa ALTINDIS (792 Turecko), Botond LAKATOS (348 Maďarsko), Catalina Mihaela LUCA (642 Rumunsko), Esmeray Mutlu YILMAZ (792 Turecko), Emmanuel NSUTEBU (784 Spojené arabské emiráty), Rumeysa CAKMAK (792 Turecko) a Fatma SIRMATEL (792 Turecko).
Vydání International Journal of Antimicrobial Agents, Amsterdam, Netherlands, Elsevier Ltd, 2023, 0924-8579.
Další údaje
Originální jazyk angličtina
Typ výsledku Článek v odborném periodiku
Obor 30303 Infectious Diseases
Stát vydavatele Nizozemské království
Utajení není předmětem státního či obchodního tajemství
WWW URL
Impakt faktor Impact factor: 10.800 v roce 2022
Kód RIV RIV/00216224:14110/23:00131722
Organizační jednotka Lékařská fakulta
Doi http://dx.doi.org/10.1016/j.ijantimicag.2023.106919
UT WoS 001063127400001
Klíčová slova anglicky Febrile neutropenia; Bacteraemia; Antimicrobial; Resistance; Antibiotic stewardship
Štítky 14110214, rivok
Příznaky Mezinárodní význam, Recenzováno
Změnil Změnila: Mgr. Tereza Miškechová, učo 341652. Změněno: 1. 2. 2024 13:35.
Anotace
Objectives: Bacteraemia during the course of neutropenia is often fatal. We aimed to identify factors predicting mortality to have an insight into better clinical management.Methods: The study has a prospective, observational design using pooled data from febrile neutropenia patients with bacteraemia in 41 centres in 16 countries. Polymicrobial bacteraemias were excluded. It was performed through the Infectious Diseases-International Research Initiative platform between 17 March 2021 and June 2021. Univariate analysis followed by a multivariate binary logistic regression model was used to determine independent predictors of 30-d in-hospital mortality (sensitivity, 81.2%; specificity, 65%). Results: A total of 431 patients were enrolled, and 85 (19.7%) died. Haematological malignancies were detected in 361 (83.7%) patients. Escherichia coli (n = 117, 27.1%), Klebsiellae (n = 95, 22% %), Pseudomonadaceae (n = 63, 14.6%), Coagulase-negative Staphylococci (n = 57, 13.2%), Staphylococcus aureus (n = 30, 7%), and Enterococci (n = 21, 4.9%) were the common pathogens. Meropenem and piperacillin-tazobactam susceptibility, among the isolated pathogens, were only 66.1% and 53.6%, respectively. Pulse rate (odds ratio [OR], 1.018; 95% confidence interval [CI], 1.002-1.034), quick SOFA score (OR, 2.857; 95% CI, 2.120- 3.851), inappropriate antimicrobial treatment (OR, 1.774; 95% CI, 1.011-3.851), Gram-negative bacteraemia (OR, 2.894; 95% CI, 1.437-5.825), bacteraemia of non-urinary origin (OR, 11.262; 95% CI, 1.368-92.720), and advancing age (OR, 1.017; 95% CI, 1.001-1.034) were independent predictors of mortality. Bacteraemia in our neutropenic patient population had distinctive characteristics. The severity of infection and the way to control it with appropriate antimicrobials, and local epidemiological data, came forward. Conclusions: Local antibiotic susceptibility profiles should be integrated into therapeutic recommendations, and infection control and prevention measures should be prioritised in this era of rapidly increasing antibiotic resistance.
VytisknoutZobrazeno: 22. 5. 2024 05:29